TOP TEN perturbations for 11760115_x_at (Homo sapiens)

Organism: Homo sapiens
Gene: 11760115_x_at
Selected probe(set): 217317_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 11760115_x_at (217317_s_at) across 5779 perturbations tested by GENEVESTIGATOR:

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):4.8236485
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):4.227503
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):4.0070534
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):3.834299
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):3.8040972
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

tunicamycin study 2 (2ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):3.6961489
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):3.5998878
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):3.481018
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):3.3639336
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

hepatocyte (ESC) / Hep-G2

Relative Expression (log2-ratio):-3.1018791
Number of Samples:8 / 9
Experimental hepatocyte (ESC)
Hepatocyte-like cells differentiated from embryonic stem cells (ESC)
Control Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:

Organism: Homo sapiens
Gene: 11760115_x_at
Selected probe(set): 215847_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 11760115_x_at (215847_at) across 5779 perturbations tested by GENEVESTIGATOR:

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-2.309918
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; metastase) / fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; primary)

Relative Expression (log2-ratio):-2.2906942
Number of Samples:6 / 2
Experimental fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; metastase)
Metastatic tumor tissue samples obtained from different anatomical sites (bone, colon, ovary and peritoneum) of female patients with primary papillary serous cystadenocarcinoma of the fallopian tube.
Control fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; primary)
Primary tumor tissue samples obtained from the fallopian tube of female patients with papillary serous cystadenocarcinoma.

ovarian tumor study 27 (papillary serous cystadenocarcinoma; primary) / fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; primary)

Relative Expression (log2-ratio):-2.2638035
Number of Samples:153 / 2
Experimental ovarian tumor study 27 (papillary serous cystadenocarcinoma; primary)
Primary tumor tissue samples obtained from the ovary of female patients with papillary serous cystadenocarcinoma.
Control fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; primary)
Primary tumor tissue samples obtained from the fallopian tube of female patients with papillary serous cystadenocarcinoma.

peritoneal tumor study 1 (papillary serous cystadenocarcinoma; primary) / fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; primary)

Relative Expression (log2-ratio):-2.1525793
Number of Samples:28 / 2
Experimental peritoneal tumor study 1 (papillary serous cystadenocarcinoma; primary)
Primary tumor tissue samples obtained from the peritoneum of female patients with papillary serous cystadenocarcinoma.
Control fallopian tube tumor study 1 (papillary serous cystadenocarcinoma; primary)
Primary tumor tissue samples obtained from the fallopian tube of female patients with papillary serous cystadenocarcinoma.

rheumatoid arthritis study 37 (mono; CD14+ CD16+) / rheumatoid arthritis study 37 (mono; CD14+ CD16-)

Relative Expression (log2-ratio):1.9745259
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (mono; CD14+ CD16+)
Peripheral blood CD14+ CD16+ monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm
Control rheumatoid arthritis study 37 (mono; CD14+ CD16-)
Peripheral blood CD14+ CD16- monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm

HCC study 20 (CDX; Hep-G2; ectopic) / HCC study 20 (PDX; ectopic)

Relative Expression (log2-ratio):-1.7994671
Number of Samples:3 / 11
Experimental HCC study 20 (CDX; Hep-G2; ectopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; ectopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample ectopically generated in SCID mice by injecting hepatocellular carcinoma cells subcutaneously. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish ectopic models, cells were injected subcutaneously into the flank regions. The mice were euthanized after two weeks.

HCC study 20 (CDX; Hep-G2; orthotopic) / HCC study 20 (PDX; orthotopic)

Relative Expression (log2-ratio):-1.5690966
Number of Samples:5 / 11
Experimental HCC study 20 (CDX; Hep-G2; orthotopic)
Tumor tissue biopsy samples from Hep-G2 cell line-derived xenograft (CDX) orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.
Control HCC study 20 (PDX; orthotopic)
Tumor tissue biopsy samples from patient-derived xenograft (PDX) sample orthotopically generated in SCID mice by injecting hepatocellular carcinoma cells directly into liver parenchyma. Donor tumor tissue was obtained intraoperatively during liver resection from three patients. All three patients had hepatocellular carcinoma confirmed by histology. In order to establish orthotopic model, the left lobe of liver was exposed through midline abdominal incision and cells were injected directly into liver parenchyma of mice. The mice were euthanized after two weeks.

HIV-associated neurocognitive disorder study 2 (HIVE) / HIV-associated neurocognitive disorder study 1 (HIVE)

Relative Expression (log2-ratio):1.5151558
Number of Samples:2 / 6
Experimental HIV-associated neurocognitive disorder study 2 (HIVE)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with HIV encephalitis (HIVE). The patients received an antiretroviral therapy (ART).
Control HIV-associated neurocognitive disorder study 1 (HIVE)
Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with HIV encephalitis (HIVE). The patients did not receive any antiretroviral therapy (ART).

male infertility study 1 (mJS5) / male infertility study 1 (mJS2)

Relative Expression (log2-ratio):1.5145464
Number of Samples:8 / 7
Experimental male infertility study 1 (mJS5)
Human testicular lobules biopsy samples isolated from adult infertile patients whose seminiferous tubules contained spermatocytes but no spermatids. Tissue samples were classified based on modified Johnsen score (mJS) as mJS5.
Control male infertility study 1 (mJS2)
Human testicular lobules biopsy samples isolated from adult infertile patients whose seminiferous tubules contained almost exclusively Sertoli cells. Tissue samples were classified based on modified Johnsen score (mJS) as mJS2.

ovarian tumor study 28 (clear cell adenocarcinoma) / ovarian tumor study 28 (adenocarcinoma)

Relative Expression (log2-ratio):-1.4906654
Number of Samples:6 / 3
Experimental ovarian tumor study 28 (clear cell adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma.
Control ovarian tumor study 28 (adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with adenocarcinoma.